This trial will be the catalyst for share price appreciation.
I'm keen for others thoughts on this one but it looks to me like they're planning on having the phase 2 primary completion wrapped up by mid 2026. That's a lot quicker than I anticipated and an enormous amount of confidence before they have dosed a single patient. Looking at the study overview, the estimated enrolment number of 135 patient's and the phases 1 and 2 listed would suggest as much?
Given the preclinic complete eradication of all cancer cells happened within a month, the preliminary data back end of the year is going to be of HUGE interest.
CHM Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)